| Name | Title | Contact Details |
|---|
PhotoMedex is a leader in the dermatology market, committed to the Science of Skin Health in disease management and skin rejuvenation. We focus our efforts where we can make meaningful differences in dermatological applications for psoriasis and vitiligo, therapeutic skin care and LED therapy for acne and photodamage. Our Purpose, to provide branded dermatological solutions of superior value to improve patients` lives now and into the future, is our common goal and leads our thinking. The results of which will be realized in physicians and patients rewarding us with winning sales, profit and equity generation. Our commitment to safety and efficacy is reflected in our dedication to scientific development and has led to a broad range of FDA clearances. XTRAC was the first FDA market-cleared excimer laser system for the treatment of dermatological applications, including psoriasis and vitiligo. The Omnilux LED system carries FDA clearances for skin rejuvenation, acne and pain management. Neova, the science of skin care, holds dozens of patents on its clinically proven Copper Peptide technology for skin health, hair care and wound care.
Altru Health System is a community-owned, integrated system with an acute care hospital, a specialty hospital, more than a dozen clinics in Grand Forks and the region, a large home care network, and a congregate living facility. It employs more than 200 physicians and 4,000 staff and has an annual net operating revenue of more than $450 million. As the first member of the Mayo Clinic Care Network, Altru’s providers have access to clinically integrated tools extending Mayo Clinic’s knowledge and expertise to patients.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.
American Health Care Centers is a Wadsworth, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Benchmark Research is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.